Skip to main content
. 2017 Apr 18;5:34. doi: 10.1186/s40425-017-0236-3

Fig. 2.

Fig. 2

Change in patient blood counts over course of treatment with Pembrolizumab. Panel a indicates changes in patient’s white blood cell count (K/mcL) over the period of August 2015 through April 2016. Panel b indicates changes in the patient’s hemoglobin level (g/dL) over this same time period. Panel c corresponds to changes in the patient’s platelet level (K/mcL) over this same period